PTC touts Phase 2 biomarker data for Huntington’s drug, showing dose-dependent effect at one year
PTC Therapeutics presented new biomarker data for a Huntington’s disease drug Thursday morning that it says demonstrates evidence of reducing the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
